Which startups have raised the most funding in the femtech market?
Download our beautiful pitch about the femtech market

In our femtech market deck, you will find everything you need to understand the market
The femtech market is moving from niche consumer apps into a broader healthcare category that includes fertility, maternal care, menopause, diagnostics, pelvic health, and AI-enabled care delivery.
This ranking is built to help investors, founders, and operators quickly see which femtech startups have raised the most funding to date.
We update this list every month, so the table stays useful as new rounds, acquisitions, and company updates are announced.
And if you want to better understand this new industry, you can download our pitch covering the femtech market.
A quick summary table
| Metric | Value |
|---|---|
| Most funded startup | Maven Clinic, $420M raised |
| Second most funded startup | Kindbody, $330M raised |
| Largest funding round | Willow, $175M Series C |
| Median funding | About $23M across the ranked femtech startups |
| Share of funding captured by the top 10 | About 44% of total ranked funding |
| Median time since last round | About 22 months |
| Startups that raised funding in the last 12 months | 27 startups |
| Femtech startups with $100M+ raised | 12 startups |
| Fertility and IVF funding leaders | Gameto, Natural Cycles, Conceivable Life Sciences, Overture Life, and Gaia Fertility |
| Women’s health AI and diagnostics cluster | Mercy BioAnalytics, Clairity, PinkDx, AOA Dx, Ataraxis AI, Teal Health, Vara, and BeSound |

This chart, included in our femtech market deck, shows annual VC investment in femtech startups
Top startups in the femtech market ranked by total funding raised
Here is an updated table that ranks the top startups in the femtech market based on the total amount of funding they have raised to date.
The table also includes the total number of funding rounds, the date and size of the latest round, the financing type (e.g. Series A, equity financing), key investors, the startup’s current status (active, IPO, acquired, or shut down), and a confidence score based on the data collected (we excluded startups with very low data confidence, to make sure everything is reliable).
If you're interested in knowing how much these startups are worth, you can check our list of the top startups in the femtech market ranked by valuation.
| # | Startup | What They Do | Total Raised ($) | Total Rounds | Last Round Date | Last Round Amount ($) | Last Round Type | Key Investors | Current Stage | Confidence |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Maven Clinic | Virtual women’s healthcare platform | $420M | 5 | 2023 | $155M | Extension | General Catalyst, Dragoneer, ICONIQ | Active | Partial |
| 2 | Kindbody | Fertility clinics and care network | $330M | 5 | 2023 | $120M | Extension | Perceptive Advisors, GV, Tiger Global | Active | Partial |
| 3 | Willow | Smart wearable breast pump company | $250M | 4 | 2021 | $175M | Series C | NEA, Meritech Capital, Menlo Ventures | Active | Partial |
| 4 | Elvie | Femtech health device company | $180M | 4 | 2021 | $115M | Series C | Octopus Ventures, BlackRock, BGF | Acquired | Partial |
| 5 | TMRW Life Sciences | Automated IVF cryostorage platform | $170M | 4 | July 2024 | $28M | Series D | 5AM Ventures, Casdin Capital, DF Investment Partners | Acquired | Partial |
| 6 | Tia | Hybrid women’s health clinics | $150M | 5 | 2023 | $10M | Extension | Owl Ventures, Threshold Ventures | Active | Partial |
| 7 | Gameto | Stem-cell fertility therapies | $117M | 5 | August 2025 | $44M | Series C | Overwater Ventures, Insight Partners, RA Capital | Active | Full |
| 8 | Comanche Biopharma | siRNA preeclampsia therapy | $111M | 2 | January 2024 | $75M | Series B | NEA, Atlas Venture, GV | Active | Strong |
| 9 | Diana Health | Hospital-partnered women’s clinics | $100M | 3 | September 2025 | $55M | Series C | HealthQuest Capital, Norwest Venture Partners, .406 Ventures | Active | Full |
| 10 | Natural Cycles | Digital birth-control app | $100M | 5 | May 2024 | $55M | Series C | Lauxera Capital Partners, Point72 Private Investments | Active | Strong |
| 11 | Mercy BioAnalytics | Early cancer liquid biopsies | $100M | 2 | September 2025 | $59M | Series B | Novalis, Sozo Ventures, Perceptive Xontogeny | Active | Full |
| 12 | Conceivable Life Sciences | AI automated IVF lab | $70M | 2 | September 2025 | $50M | Series A | Advance Venture Partners, ARTIS Ventures, Stride | Active | Strong |
| 13 | Pomelo Care | Maternal care digital health | $65M | 2 | 2023 | $40M | Series A | a16z, GV, First Round Capital | Active | Strong |
| 14 | ReproNovo | Reproductive medicine drug developer | $65M | 1 | May 2025 | $65M | Series A | Jeito Capital, AXA IM Alts, M Ventures | Active | Full |
| 15 | Materna Medical | Pelvic and obstetrical devices | $60M | 5 | June 2026 | $5M | Series B3 | InnovaHealth Partners, Wavemaker360 Health, Band of Angels | Active | Partial |
| 16 | Wildflower Health | Digital maternity care platform | $59M | 6 | November 2024 | $18M | Venture / Undisclosed | TT Capital Partners, Health Enterprise Partners, Echo Health Ventures | Active | Partial |
| 17 | Renovia | Pelvic floor digital therapeutics | $57M | 3 | April 2021 | $17M | Series C-1 | Parian Global Management, Perceptive Life Sciences, Longwood Fund | Acquired | Partial |
| 18 | Overture Life | IVF automation technology | $57M | 3 | April 2025 | $21M | Strategic round | Overwater Ventures, GV, Khosla Ventures | Active | Partial |
| 19 | Peppy | Employee women’s health benefits | $56M | 4 | January 2023 | $45M | Series B | AlbionVC, Felix Capital, Hambro Perks | Active | Strong |
| 20 | Gesynta Pharma | Endometriosis drug developer | $52M | 2 | July 2025 | $32M | Series B | Innovestor Life Science, HealthCap, Hadean Growth Fund | Active | Strong |
| 21 | Oula | Hybrid maternity care clinics | $50M | 3 | February 2024 | $28M | Series B | Revolution Ventures, Maverick Ventures, GV | Active | Full |
| 22 | Freya Biosciences | Women’s microbial immunotherapies | $50M | 2 | November 2024 | $12M | Series A extension | Bill & Melinda Gates Foundation, EIFO, Sofinnova Partners | Active | Full |
| 23 | Clairity | AI breast cancer risk prediction | $50M | 2 | November 2025 | $43M | Series B | ACE Global Equity, Santé Ventures, BCRF | Active | Strong |
| 24 | May Health | PCOS infertility device therapy | $48M | 3 | March 2026 | $12M | Follow-on / Extension | Sofinnova Partners, Trill Impact, Bpifrance | Active | Strong |
| 25 | Inito | At-home fertility hormone monitoring | $45M | 11 | December 2025 | $29M | Series B | Bertelsmann India Investments, Fireside Ventures, Y Combinator | Active | Partial |
| 26 | PinkDx | Gynecologic cancer diagnostics | $45M | 2 | January 2025 | $5M | Series A extension | Catalio Capital Management, The Production Board, Mountain Group Partners | Active | Full |
| 27 | Clue | Period tracking app | $44M | 9 | January 2026 | Undisclosed | Series B / Extension | Balderton Capital, Union Square Ventures, Nokia Growth Partners | Active | Partial |
| 28 | Ava | Fertility tracking wearable | $42M | 3 | May 2018 | $30M | Series B | Polytech Ventures, btov Partners, SVC | Acquired | Strong |
| 29 | Allara Health | Hormonal care platform | $39M | 3 | January 2025 | $26M | Series B | Index Ventures, GV, Global Founders Capital | Active | Strong |
| 30 | illumigyn | Remote gynecological imaging platform | $38M | 2 | November 2021 | $33M | Series B | Yozma Group Korea, Ubicom Holdings Japan | Active | Strong |
| 31 | Babyscripts | Virtual maternity care platform | $37M | 8 | November 2021 | $8M | Series B extension | Cigna Ventures, TMC Venture Fund, Atlantic Health System | Active | Partial |
| 32 | Visana Health | Virtual women’s health clinic | $37M | 3 | September 2025 | $24M | Series A | Noro-Moseley Partners, Cigna Ventures, Intermountain Ventures | Active | Strong |
| 33 | Gaia Fertility | Fertility financing and insurance | $37M | 3 | January 2025 | $14M | Series A / extension | Valar Ventures, Atomico, Kindred Capital | Active | Full |
| 34 | HerMD | Virtual women’s healthcare clinics | $36M | 3 | June 2024 | $8M | Series A extension | JAZZ Venture Partners, B-Flexion, Amboy Street Ventures | Acquired | Partial |
| 35 | Alpha Medical | Women’s virtual primary care | $35M | 2 | September 2021 | $24M | Series B | SpringRock Ventures, Samsung Next, GSR Ventures | Active | Strong |
| 36 | AOA Dx | Ovarian cancer blood test | $35M | 5 | October 2025 | $8M | Series A | Not disclosed | Active | Partial |
| 37 | Axena Health | Pelvic health medical device | $34M | 2 | June 2024 | $9M | Series A extension | Cross-Border Impact Ventures, AXA IM Alts, Avestria Ventures | Active | Full |
| 38 | Bloomlife | Remote pregnancy monitoring | $34M | 5 | September 2025 | $8M | Venture round | Kapor Capital, Noshaq, Marc Benioff | Active | Partial |
| 39 | Stork Club | Family-building employee benefits | $33M | 2 | June 2021 | $30M | Series A | General Catalyst, Bowery Capital, Slow Ventures | Active | Full |
| 40 | Alife Health | AI IVF optimization platform | $32M | 2 | March 2022 | $22M | Series A | Union Square Ventures, Lux Capital, Maveron | Active | Full |
| 41 | Sonio | AI prenatal ultrasound software | $30M | 3 | July 2023 | $14M | Series A | Cross-Border Impact Ventures, Elaia, EIC | Acquired | Partial |
| 42 | Evernow | Menopause telehealth care | $29M | 1 | April 2022 | $29M | Series A | NEA, 8VC, Refactor Capital | Active | Full |
| 43 | Caraway | Gen Z virtual healthcare | $27M | 2 | June 2023 | $17M | Series A | Maveron, GV, 7wireVentures | Active | Full |
| 44 | Twentyeight Health | Reproductive telehealth access | $25M | 5 | January 2025 | $10M | Series A | Seae Ventures, Impact America Fund, RH Capital | Active | Partial |
| 45 | AIVF | AI IVF clinic software | $25M | 1 | June 2022 | $25M | Series A | Insight Partners, 166 2nd, Alora Ventures | Active | Full |
| 46 | Ataraxis AI | AI cancer precision medicine | $24M | 2 | March 2025 | $20M | Series A | AIX Ventures, Floating Point, Thiel Bio | Active | Full |
| 47 | Teal Health | At-home cervical cancer screening | $23M | 4 | January 2025 | $10M | Seed extension | Emerson Collective, Forerunner Ventures, Serena Ventures | Active | Strong |
| 48 | Univfy | AI IVF success prediction | $22M | 6 | December 2021 | $6M | Series B | Atlantic Street Capital, Rethink Impact, Ignite Healthcare Network | Active | Partial |
| 49 | Delfina | AI maternal care platform | $22M | 2 | January 2025 | $17M | Series A | USVP, ARTIS Ventures, Mayo Clinic | Active | Strong |
| 50 | Vara | AI breast cancer screening | $20M | 3 | October 2024 | $9M | Series A | IBB Ventures, Smart Family Office, FJH | Active | Strong |
| 51 | Inne | At-home hormone tracking minilab | $19M | 2 | May 2022 | $10M | Series A | DSM Venturing, Blossom Capital, Borski Fund | Active | Strong |
| 52 | Alloy Women’s Health | Menopause telehealth care | $19M | 2 | November 2024 | $16M | Series A | Kairos HQ, PACE Healthcare Capital, Emmeline Ventures | Active | Full |
| 53 | Daye | Diagnostic menstrual health products | $19M | 4 | November 2025 | $1M | Series A extension | Index Ventures, MassMutual Ventures, Hambro Perks | Active | Strong |
| 54 | Evvy | Vaginal microbiome testing platform | $19M | 2 | September 2023 | $14M | Series A | Left Lane Capital, General Catalyst, Labcorp Venture Fund | Active | Full |
| 55 | MobileODT | Smartphone cervical cancer diagnostics | $17M | 5 | August 2020 | $4M | Series C | OrbiMed, Tristel, Tara Health | Acquired | Partial |
| 56 | Millie | Hybrid maternity care clinic | $16M | 2 | February 2025 | $12M | Series A | TMV, Foreground Capital, Pivotal Ventures | Active | Full |
| 57 | Mahmee | Maternal care coordination platform | $16M | 7 | May 2022 | $9M | Series A | Goldman Sachs Asset Management, 500 Global, Acumen | Active | Strong |
| 58 | NextGen Jane | Menstrual diagnostics platform | $16M | 5 | October 2023 | Undisclosed | Series B | Material Impact, Access Industries, Viking Global Investors | Active | Partial |
| 59 | Cayaba Care | Underserved maternity care services | $15M | 2 | May 2022 | $12M | Series A | Seae Ventures, Kapor Capital, Flare Capital | Active | Full |
| 60 | OCON Healthcare | Intrauterine drug-delivery devices | $14M | 4 | June 2024 | $10M | Series B | RH Capital, Pontifax, Astia Angels | Active | Partial |
| 61 | Vira Health | Digital menopause therapeutics | $14M | 3 | March 2022 | $12M | Series A | Octopus Ventures, Optum Ventures, LocalGlobe | Active | Strong |
| 62 | Hertility Health | Reproductive hormone diagnostics | $14M | 2 | October 2024 | Undisclosed | Angel / Seed extension | Emma Watson, Phoenix Court, Venrex | Active | Partial |
| 63 | Oova | At-home fertility hormone tracking | $13M | 3 | June 2023 | $10M | Series A | Spero Ventures, US Fertility, Virgin Group | Active | Strong |
| 64 | Elektra Health | Menopause virtual care platform | $12M | 5 | January 2025 | $5M | Series B | UPMC Enterprises, Flare Capital Partners, Seven Seven Six | Active | Partial |
| 65 | Cofertility | Egg freezing and donation | $12M | 2 | April 2025 | $7M | Series A | Next Ventures, Offline Ventures, Initialized Capital | Active | Partial |
| 66 | Womed | Intrauterine uterine health therapies | $12M | 2 | June 2026 | $5M | Equity financing | IRDI Capital Investissement, institutional investors | Active | Partial |
| 67 | Dorsata | Obstetrics EHR workflow software | $11M | 6 | April 2020 | $5M | Series A | QED Investors, Labcorp, Motley Fool Ventures | Active | Partial |
| 68 | Hormona | At-home hormone tracking | $11M | 3 | May 2025 | $7M | Seed | Voima Ventures, SuperNode Global VC, Techstars | Active | Partial |
| 69 | iSono Health | Wearable breast ultrasound imaging | $11M | 4 | 2025 | $3M | Seed Preferred | Draper Associates, Transform VC, JSK Venture | Active | Partial |
| 70 | Plenna | Hybrid women’s health clinics | $11M | 3 | May 2025 | $6M | Series A | Mazapil, Dalus Capital, New Ventures | Active | Strong |
| 71 | Gynoveda | Ayurveda menstrual health platform | $11M | 2 | March 2023 | $10M | Series A | India Alternatives, Wipro Enterprises, RPG Ventures | Active | Strong |
| 72 | Proov | At-home hormone fertility tests | $10M | 2 | December 2021 | $10M | Series A | Hambrecht Ducera Growth Ventures, SteelSky Ventures, Portfolia | Active | Partial |
| 73 | Hey Jane | Virtual reproductive healthcare clinic | $8M | 2 | October 2022 | $6M | Series A | Ulu Ventures, The Helm, Amboy Street Ventures | Active | Full |
| 74 | Lady Technologies | Fertility tracker and pelvic trainer | $8M | 2 | January 2025 | $7M | Series A | Relentless Consumer Partners, SOSV, Texas HALO Fund | Active | Strong |
| 75 | BioAesthetics | Nipple-areolar graft reconstruction | $8M | 3 | December 2020 | $5M | Series A | FemHealth Ventures, Sandra Coufal, Hemi Ventures | Active | Partial |
| 76 | Fertifa | Employer fertility benefits | $8M | 4 | May 2023 | $6M | Seed | Notion Capital, Triple Point Ventures, Passion Capital | Active | Partial |
| 77 | Nua Surgical | C-section surgical retractor | $7M | 1 | December 2024 | $7M | Series A | EQT Life Sciences, TMC Venture Fund, Kidron Capital | Active | Full |
| 78 | BeSound | Dense-breast cancer screening | $7M | 1 | September 2025 | $7M | Seed | Overwater Ventures, Kindred Ventures, Muse Capital | Active | Full |
| 79 | Iron Health | Virtual women’s care platform | $5M | 1 | March 2023 | $5M | Seed | March of Dimes, Redesign Health | Active | Full |
| 80 | Conceive | Digital fertility support | $5M | 2 | July 2024 | $1M | Seed extension | Kindred Ventures, Founder Collective, Great Oaks | Active | Strong |
| 81 | Pelvital | Pelvic floor therapy device | $5M | 2 | April 2024 | $2M | Seed Plus | Boomerang Ventures, Pier 70 Ventures, Life Science Angels | Active | Full |
| 82 | Fizimed | Connected pelvic rehab devices | $5M | 2 | March 2025 | $4M | Growth / Venture | Bpifrance, UNIQA Ventures, UI Investissement | Active | Strong |
| 83 | Escala Medical | Pelvic prolapse repair device | $5M | 1 | June 2025 | $5M | Series A | EIC Fund, U.S. private investors, Israeli private investors | Active | Partial |
| 84 | TBD Health | Hybrid sexual healthcare provider | $4M | 2 | January 2023 | $4M | Seed | Tusk Venture Partners, Springdale Ventures, Human Ventures | Active | Strong |
| 85 | Gennev | Menopause telehealth platform | $4M | 3 | July 2019 | $4M | Seed / Series A | BlueRun Ventures, Maven Ventures, StartUp Health | Acquired | Partial |
| 86 | Apryl | Fertility benefits platform | $4M | 1 | April 2022 | $4M | Seed | Breega, Ventech, Atlantic Labs | Acquired | Strong |
| 87 | Béa Fertility | At-home fertility treatment | $4M | 3 | November 2023 | Undisclosed | Strategic / Follow-on | Pioneer Group, Octopus Ventures, Calm/Storm Ventures | Active | Partial |
| 88 | Juno Bio | Vaginal microbiome testing | $3M | 3 | September 2023 | $3M | Late Seed | Ada Ventures, Illumina, Entrepreneur First | Active | Partial |
| 89 | Partum Health | Pregnancy postpartum support care | $3M | 1 | September 2023 | $3M | Seed | True Wealth Ventures, MAGIC Fund, The Fund Midwest | Active | Full |
| 90 | Uresta | Bladder leakage support device | $3M | 1 | March 2025 | $3M | Seed | BDC Capital, NBIF, Cassiar Partners | Active | Strong |
| 91 | Chiyo | Maternal nutrition meal programs | $3M | 1 | March 2024 | $3M | Seed | Bread & Butter Ventures, Union Heritage Ventures, Peterson Ventures | Active | Strong |
| 92 | Bird&Be | Fertility supplements and tests | $2M | 1 | September 2021 | $2M | Seed | BAM Ventures, Slow Ventures, HaloHealth | Active | Full |
| 93 | Aster Health | Predictive pregnancy care platform | $2M | 1 | January 2024 | $2M | Seed | Cake Ventures, Cornerstone VC, Octopus Ventures | Active | Full |
| 94 | Salva Health | Breast cancer screening device | $1M | 2 | September 2025 | $0M | Seed | Epic Angels, EWA Capital, Village Capital | Active | Partial |

This market map, featured in our femtech market deck, highlights top companies and startups in the femtech market
Key funding trends in the femtech market
Insights
- The femtech market is still concentrated at the top, with the ten most funded startups capturing about 44% of all funding in the ranked dataset.
- Fertility, IVF, and reproductive health remain the deepest funding themes, with Maven Clinic, Kindbody, TMRW Life Sciences, Gameto, Natural Cycles, and Conceivable Life Sciences leading the category.
- AI-enabled femtech is becoming a serious funding cluster, especially across IVF automation, maternal care, cancer screening, and women’s health risk prediction.
- Women’s cancer diagnostics is one of the most investable femtech subcategories, with Mercy BioAnalytics, Clairity, PinkDx, AOA Dx, Teal Health, Vara, and BeSound all raising institutional capital.
- Most femtech startups are still early or mid-stage, since many ranked companies have only one to three disclosed rounds despite meaningful investor interest.
- Recent funding activity is healthy, with 27 ranked femtech startups raising capital in the last 12 months, including Materna Medical, Womed, May Health, Inito, Clairity, and Diana Health.
- Menopause and hormonal health are visible but less mature funding categories, with companies such as Allara Health, Evernow, Alloy Women’s Health, Elektra Health, and Vira Health still below the largest fertility platforms.

As this chart shows, and as featured in our femtech market deck, search interest in femtech has increased significantly
A few word about our methodology
As you can see, we built a database that ranks startups in the femtech market based on their total cumulative fundraising. To create this ranking, we reviewed many sources and cross-checked information across multiple places.
Whenever possible, we prioritized official company communications, since they are the most reliable source for funding amounts. When those were not available, we relied on reputable industry sources such as TechCrunch, Crunchbase, Financial Times or Forbes (to name a few).
We excluded random blogs, unverified websites, and any sources that could not be validated.
When funding rounds were announced in other currencies such as euros, Swiss francs, Singapore dollars, Australian dollars, or rupees, we converted them into approximate USD equivalents for consistency.
Sometimes different sources report slightly different numbers, or the exact round size is not fully disclosed. In those cases, we flag the uncertainty and assign a confidence label to each startup, visible in the last column.
Here is what they mean.
Full confidence: The company’s equity fundraising history can be reconstructed completely from public sources. The rounds, dates, amounts, and key investors are clearly identified, with no meaningful gaps.
Strong confidence: The fundraising history is largely complete and reliable. There may be a small missing detail, such as incomplete investor information or a minor round with limited data, but the overall record is clear.
Partial confidence: The main fundraising rounds can be identified, but the record is incomplete or somewhat mixed. Some rounds may be missing or certain funding events may be difficult to separate clearly.
Low confidence: Public information is too limited, inconsistent, or ambiguous to reliably reconstruct the company’s equity fundraising history.
When the confidence level is too low, we take a conservative approach and exclude the company from the ranking. We don’t want to include data that cannot be reliably verified.
This reflects how we conduct all our research, including the work behind our report covering the femtech market.
In a world where LLMs hallucinate and unreliable information is everywhere, our goal is simple: provide data you can trust.
If you want the full detail on a specific calculation, feel free to contact us and we will gladly explain.
Finally, know that we update the dataset once per month, so come back here if you need fresh information.

This chart, included in our femtech market deck, shows how Flo Health is capturing share in femtech
Related blog posts
- The most recent news in the femtech market
- The latest funding news in the femtech market
- The latest developments in the femtech market
- How funding activity has evolved in the femtech market
- What are the key fundraising trends in the femtech market?
Who is the author of this content?
NEW MARKET PITCH TEAM
We track new markets so founders and investors can move fasterWe build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page. You can also follow us on Instagram or on Facebook.
How we created this content 🔎📝
At New Market Pitch, we kept seeing the same problem: when you look at a new market, the data is either missing, paywalled, or buried in 300-page reports that feel like they were written in the 80s. On the other side, LLMs and random blog posts give you confident answers with no sources, and sometimes they just make things up. That’s not good enough when you’re about to invest real money or launch a company.
So we decided to fix the experience. For each market we cover, we build a structured database and update it on a regular basis. We track funding rounds, fund memos, M&A moves, partnerships, new products, policy changes, and the real activity of startups and incumbents. Then we turn all of that into a clear “market pitch” that shows where the opportunities are and how people actually win in that space.
Every key data point is checked, sourced, and put back into context by our team. That’s how we can give you both speed and reliability: fast coverage of new markets, without the usual guesswork.